Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SLSolid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB)

NASDAQ Global Select · Currency in USD
$5.92 ▼ -0.27 (-4.36%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.95 ▲ +0.03 (+0.51%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$6.19
Open
$6.12
Day's Range
$5.78 – $6.15
52 Week Range
$3.79 – $11.45
Volume
769,962
Avg. Volume
1,523,388
Market Cap
$634.77M
Beta (5Y Monthly)
2.47
PE Ratio (TTM)
--
EPS (TTM)
-$1.89
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$20.50

Profile: Solid Biosciences Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
121
CEO
Alexander G. Cumbo

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate -$0.37
DateEst.Actual
Aug 6, 2026-$0.46-$0.38Beat
May 12, 2026-$0.40-$0.52Miss
Mar 19, 2026-$0.51-$0.50Beat
Nov 3, 2025-$0.42-$0.48Miss
Aug 12, 2025-$0.51-$0.42Beat
May 15, 2025-$0.53-$0.59Miss

Analyst view

Consensus price target
$20.50 ▲ +246.3%
Range $16.00 – $26.00
Rating: Buy
Buy 78% · Hold 22% · Sell 0%

Get free alerts on SLDB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.